The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

NCT03558607 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder

Interventions

DRUG: Ruxolitinib

Sponsor

Seoul National University Hospital